158 related articles for article (PubMed ID: 37748807)
1. Reliability and responsiveness of the D12 and validity of its scores as a measure of dyspnoea severity in patients with rheumatoid arthritis-related interstitial lung disease.
Swigris JJ; Danoff S; Dellaripa PF; Doyle TJ; Solomon JJ
BMJ Open Respir Res; 2023 Sep; 10(1):. PubMed ID: 37748807
[TBL] [Abstract][Full Text] [Related]
2. Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.
Wallace B; Kafaja S; Furst DE; Berrocal VJ; Merkel PA; Seibold JR; Mayes MD; Khanna D
Rheumatology (Oxford); 2015 Aug; 54(8):1369-79. PubMed ID: 25667436
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability.
Topcu A; Mursaloglu HH; Yalcinkaya Y; Karakurt S; Yagiz B; Alaca Z; Demir M; Coskun BN; Dalkilic E; Inanc N
Clin Rheumatol; 2021 Sep; 40(9):3797-3805. PubMed ID: 33811590
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes to assess dyspnoea in interstitial lung disease and pulmonary hypertension: a systematic literature review of measurement properties.
Lemmers JMJ; Vonk MC; van den Ende CHM
Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36543348
[TBL] [Abstract][Full Text] [Related]
5. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation.
Yazdani A; Singer LG; Strand V; Gelber AC; Williams L; Mittoo S
J Heart Lung Transplant; 2014 May; 33(5):514-20. PubMed ID: 24630861
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary rehabilitation for interstitial lung disease.
Dowman L; Hill CJ; May A; Holland AE
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD006322. PubMed ID: 34559419
[TBL] [Abstract][Full Text] [Related]
7. Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.
Natalini JG; Swigris JJ; Morisset J; Elicker BM; Jones KD; Fischer A; Collard HR; Lee JS
Respir Med; 2017 Jun; 127():1-6. PubMed ID: 28502413
[TBL] [Abstract][Full Text] [Related]
8. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
[TBL] [Abstract][Full Text] [Related]
9. Reliability and validity of Chinese version of a tool to assess the quality of life in idiopathic pulmonary fibrosis in patients with interstitial lung disease.
Pan RL; Swigris JJ; Zhao YW; Guo AM; Wu Q; Li SJ
Int J Nurs Sci; 2019 Jan; 6(1):38-42. PubMed ID: 31406867
[TBL] [Abstract][Full Text] [Related]
10. A first look at the reliability, validity and responsiveness of L-PF-35 dyspnea domain scores in fibrotic hypersensitivity pneumonitis.
Swigris JJ; Aronson K; Fernández Pérez ER
BMC Pulm Med; 2024 Apr; 24(1):188. PubMed ID: 38641768
[TBL] [Abstract][Full Text] [Related]
11. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases.
Swigris JJ; Bushnell DM; Rohr K; Mueller H; Baldwin M; Inoue Y
BMJ Open Respir Res; 2022 Mar; 9(1):. PubMed ID: 35241434
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
14. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease.
Kreuter M; Hoffmann-Vold AM; Matucci-Cerinic M; Saketkoo LA; Highland KB; Wilson H; Alves M; Erhardt E; Schoof N; Maher TM
Rheumatology (Oxford); 2023 Feb; 62(SI):SI43-SI53. PubMed ID: 35640959
[TBL] [Abstract][Full Text] [Related]
15. Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease.
Suzuki A; Kondoh Y; Swigris JJ; Ando M; Kimura T; Kataoka K; Yamano Y; Furukawa T; Numata M; Sakamoto K; Hasegawa Y
Respirology; 2018 Mar; ():. PubMed ID: 29575410
[TBL] [Abstract][Full Text] [Related]
16. Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis.
Bacci ED; DeLozier AM; Lin CY; Gaich CL; Zhang X; Rooney T; de Bono S; Hoffman R; Wyrwich KW
Health Qual Life Outcomes; 2017 Dec; 15(1):237. PubMed ID: 29208004
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
[TBL] [Abstract][Full Text] [Related]
18. Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease.
Suzuki A; Kondoh Y; Swigris JJ; Matsuda T; Kimura T; Kataoka K; Ando M; Hashimoto N; Sakamoto K; Hasegawa Y
Respir Med; 2019 Apr; 150():15-20. PubMed ID: 30961943
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung diseases specific measures in exercise interventions: A systematic review of measurement properties.
Oliveira A; Habash R; Ellerton L; Maybank A; Alsubheen S; Marques A; Goldstein R; Brooks D
Ann Phys Rehabil Med; 2023 Feb; 66(1):101682. PubMed ID: 35659584
[TBL] [Abstract][Full Text] [Related]
20. The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.
Birring SS; Bushnell DM; Baldwin M; Mueller H; Male N; Rohr KB; Inoue Y
Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34764181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
